POM-V Prescription Required Companion Animal

Animeloxan 5 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Meloxicam

Form

Injection

Species

Cats Dogs

Manufacturer

aniMedica GmbH

VMD MA No.

24745/4014

What it's used for

Dogs: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation followin...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Animeloxan 5 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.

Dogs:
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal
disorders. Reduction of post-operative pain and inflammation following orthopaedic
and soft tissue surgery.
Cats:
Reduction of post-operative pain after ovariohysterectomy and minor soft tissue
surgery.

Dogs:
Musculo-skeletal disorders:
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e.
0.4 ml/10 kg body weight).
Animeloxan 1.5 mg/ml oral suspension for dogs may be used for continuation of
treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after
administration of the injection.
Reduction of post-operative pain (over a period of 24 hours):
Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg
body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of
induction of anaesthesia.
Cats:
Reduction of post-operative pain:
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e.
0.06 ml/kg body weight) before surgery, for example at the time of induction of
anaesthesia.
Particular care should be taken with regard to the accuracy of dosing.
Avoid introduction of contamination during use.

Revised: October 2023
AN: 00343/2023 & 00876/2023

Do not use in animals suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

Revised: October 2023
AN: 00343/2023 & 00876/2023

Typical adverse drug reactions of NSAIDs such as loss of appetite, vomiting,
diarrhoea, faecal occult blood, apathy and renal failure have occasionally been
reported. In very rare cases elevated liver enzymes have been reported.
In very rare cases, haemorrhagic diarrhoea, haematemesis and gastrointestinal
ulceration have been reported.
These side effects occur generally within the first treatment week and are in most
cases transient and disappear following termination of the treatment but in very rare
cases may be serious or fatal.
In very rare cases anaphylactoid reactions may occur and should be treated
symptomatically.
Injection site pain.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

Revised: October 2023
AN: 00343/2023 & 00876/2023
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

None.

Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity. During anaesthesia, monitoring and fluid therapy
should be considered as standard practice.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Accidental self-injection may give rise to pain. People with known hypersensitivity to
non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the
veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
If accidental skin contact occurs, wash the affected area thoroughly. Wash hands
after use.
NSAIDs and other prostaglandin inhibitors are known to have adverse effects on
pregnancy and/or embryofoetal development.
Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have
shown evidence of foetotoxic effects.
Women of childbearing age, pregnant women or women suspected of being pregnant
should use the veterinary medicinal product with serious caution to avoid accidental
self-injection.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Animeloxan must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should
be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or
subcutaneous fluid therapy during anaesthesia should be taken into consideration.
When anaesthesia and NSAID are concomitantly administered, a risk for renal
function cannot be excluded.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such veterinary
medicinal products should be observed for at least 24 hours before commencement
of treatment. The treatment-free period, however, should take into account the
pharmacological properties of the products used previously.

Not applicable.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.